Morgan Stanley
CNTB

Morgan Stanley’s Connect Biopharma Holdings CNTB Stock Holding History

Morgan Stanley’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.41K Buy
3,590
+1,381
+63% +$3.6K ﹤0.01% 6965
2025
Q4 		$6.23K Buy
2,209
+2,109
+2,109% +$4.5K ﹤0.01% 7013
2025
Q3 		$151 Hold
100
– – ﹤0.01% 7627
2025
Q2 		$98 Buy
+100
New +$80 ﹤0.01% 7652
2024
Q3 		– Sell
-3,568
Closed -$5.42K – 7944
2024
Q2 		$5.42K Buy
+3,568
New +$5.86K ﹤0.01% 6829
2023
Q4 		– Sell
-1
Closed -$1 – 7840
2023
Q3 		$1 Hold
1
– – ﹤0.01% 7600
2023
Q2 		$1 Hold
1
– – ﹤0.01% 7643
2023
Q1 		$1 Sell
1
-358
-100% -$390 ﹤0.01% 7701
2022
Q4 		$311 Sell
359
-7,732
-96% -$6.37K ﹤0.01% 7604
2022
Q3 		$10K Sell
8,091
-64
-0.8% -$77 ﹤0.01% 7062
2022
Q2 		$7K Sell
8,155
-681
-8% -$1K ﹤0.01% 7309
2022
Q1 		$27K Buy
8,836
+3,537
+67% +$14.9K ﹤0.01% 7005
2021
Q4 		$27K Buy
+5,299
New +$58.9K ﹤0.01% 7090
2021
Q3 		– Sell
-1,197
Closed -$23K – 7943
2021
Q2 		$23K Buy
+1,197
New +$20K ﹤0.01% 6954

Other funds holding CNTB

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Morgan Stanley's CNTB Position: Q1 2026 in Review

Morgan Stanley increased its Connect Biopharma Holdings (CNTB) stake by 63% in Q1 2026, buying an estimated $3.6K and bringing the position to 3,590 shares worth $9.41K. The position accounts for ﹤0.01% of the portfolio, ranked #6965.

Morgan Stanley first reported a position in CNTB in Q2 2021 and has held it in 14 quarters since. The position peaked at $27K in Q1 2022. 41 funds tracked by Wall St. Rank hold CNTB as of Q1 2026.

  • Morgan Stanley held 3,590 shares of Connect Biopharma Holdings worth $9.41K as of Q1 2026.
  • Morgan Stanley bought 1,381 Connect Biopharma Holdings shares in Q1 2026, an estimated $3.6K.
  • Connect Biopharma Holdings made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #6965 holding.
  • Morgan Stanley first reported a position in Connect Biopharma Holdings in Q2 2021 and has held it in 14 quarters since.
  • Morgan Stanley's Connect Biopharma Holdings position peaked at $27K in Q1 2022.
  • 41 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.